Is Gilenya Approved for MS?
Yes, Gilenya (fingolimod) is FDA-approved for treating relapsing forms of multiple sclerosis (MS) in adults and children aged 10 and older. It reduces relapses, MRI lesions, and disability progression in relapsing-remitting MS (RRMS), the most common type.[1]
How Does Gilenya Work for MS?
Gilenya traps immune cells in lymph nodes, preventing them from attacking the central nervous system. Patients take one 0.5 mg capsule daily; effects start within weeks, with full benefits after 6 months.[1][2]
What MS Types Does It Treat?
Approved for clinically isolated syndrome, RRMS, and active secondary progressive MS. Not for primary progressive MS.[1]
Common Side Effects and Risks
Headache, back pain, high blood pressure, and elevated liver enzymes occur frequently. Serious risks include slow heart rate (first-dose monitoring required), infections, macular edema, and progressive multifocal leukoencephalopathy (PML). Not recommended during pregnancy due to fetal harm.[1][2]
How Does Gilenya Compare to Other MS Drugs?
| Drug | Class | Dosing | Key Edge Over Gilenya |
|------|--------|--------|----------------------|
| Ocrevus (ocrelizumab) | Monoclonal antibody | IV every 6 months | Better for primary progressive MS |
| Tecfidera (dimethyl fumarate) | Oral immunomodulator | Twice daily | Fewer cardiac risks |
| Kesimpta (ofatumumab) | Monoclonal antibody | Monthly self-injection | Faster onset, home use |
Gilenya offers once-daily oral convenience but requires ECG monitoring unlike injectables.[2]
When Does Gilenya's Patent Expire?
Core patents expired in 2019, enabling generics like fingolimod from Teva and others. Brand exclusivity ended earlier; check DrugPatentWatch.com for litigation updates on remaining formulation patents.[3]
Who Makes Gilenya and What's the Cost?
Novartis manufactures it. List price is about $8,000–$9,000 monthly without insurance; patient assistance programs reduce it for eligible users.[2]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022527s022lbl.pdf
[2] Novartis Gilenya Site: https://www.gilenya.com/
[3] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/GILENYA